JNJ:Johnson & Johnson Snapshot | Charting | News | Options
$265.58 NYSE 10:56p ET
August 5 '26 		A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appoin... GlobeNewswire
Last  Change Exchange
Market data is delayed by at least 15 minutes.
Markets Portfolio
    Symbol Lookup
    Latest Story
    A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
     GlobeNewswire
    Full Story →

    Headline News
    Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
    10:53p ET August 5 '26 GlobeNewswire
    Johnson & Johnson's RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
    8:30a ET July 30 '26 PR Newswire
    Johnson & Johnson's RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
    8:29a ET July 30 '26 PR Newswire
    More News →
    Day  0.29%Week  3.51%Month  1.34%More Charting →
    September 11 '26. Markets Closed.
    Last $265.58
    Day change   0.29%$0.77
    Open $268.03
    Gap at open $1.68
    Previous close $266.35
    Trading volume 4,706,291
    10 Day avg vol. 6,172,584
    Shares out. 2.4Bil
    Market cap. $640.0Bil
    Trading activity Below Avg.
    Previous data from yesterday, September 10 '26.

    Historical Price Performance
    3 month   10.26% 
    6 month   9.21% 
    1 year   49.15% 
    2 year   61.31% 

    Earnings
    Previous 12m $8.62
    Next 12m Estimate $11.29
    P/E ratio 30.8x
    Revenue 97,929Mil

    Market data provided by News provided by


    This site is published in the United States for U.S. residents only. The services offered within this site are available exclusively through our U.S. Financial Advisors. Stifel Nicolaus Financial Advisors may only conduct business with residents of the state in which they are properly registered. The information on this website is not an offer to sell or a solicitation of an offer to buy, any security, nor shall any such security be offered or sold to any person in any jurisdiction in which such offer, solicitation, purchase or sale may not lawfully be made.
    Important Disclosures | Privacy Notice | HIPAA Policy | Use of Information Policy | Business Continuity | Canada Trade Matching Statement

    Stifel, Nicolaus & Co., Inc. Member NYSE, FINRA, and SIPC.
    Stifel Nicolaus Canada Inc., is a member of CIPF/FCPE and IIROC
    Copyright © 2026 All rights reserved.